Figure 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis

ctDNA analysis using the NB-ALK sequencing panel. Pink areas denote parts of the ALK gene included in the panel. Recurrent mutations previously detected in neuroblastoma or associated with resistance to TKIs that are covered by the panel are shown; neuroblastoma hotspot mutations are bold. Angled numbers denote the range of ALK amino acid positions covered by each of the seven assays.